Polycystic ovary syndrome and risks for COVID-19 infection: A comprehensive review

• Published in: Reviews in endocrine & metabolic disorders 2022-04, Vol.23 (2), p.251-264
• Main Authors: de Medeiros, Sebastião Freitas, Yamamoto, Márcia Marly Winck, de Medeiros, Matheus Antônio Souto, Yamamoto, Ana Karine Lin Winck, Barbosa, Bruna Barcelo
• Format: Article
• Language: English
• Subjects: Carbohydrate metabolism; Comorbidity; Coronaviruses; COVID-19; Diabetes mellitus; Dyslipidemia; Epidemiology; Hypertension; Infection; Infections; Lipid metabolism; Metabolic disorders; Morbidity; Obesity; Ovaries; Physiological aspects; Polycystic ovary syndrome; Reviews; Severe acute respiratory syndrome coronavirus 2; Stein-Leventhal syndrome
• ISSN: 1389-9155; 1573-2606
• DOI: 10.1007/s11154-022-09715-y

This comprehensive review aimed to evaluate the relationship between SARS-CoV-2 infection (the cause of coronavirus disease 2019, or COVID-19) and the metabolic and endocrine characteristics frequently found in women with polycystic ovary syndrome (PCOS). In the general population, COVID-19 is more severe in subjects with dyslipidemia, obesity, diabetes mellitus, and arterial hypertension. Because these conditions are comorbidities commonly associated with PCOS, it was hypothesized that women with PCOS would be at higher risk for acquiring COVID-19 and developing more severe clinical presentations. This hypothesis was confirmed in several epidemiological studies. The present review shows that women with PCOS are at 28%-50% higher risk of being infected with the SARS-CoV-2 virus at all ages and that, in these women, COVID-19 is associated with increased rates of hospitalization, morbidity, and mortality. We summarize the mechanisms of the higher risk of COVID-19 infection in women with PCOS, particularly in those with carbohydrate and lipid abnormal metabolism, hyperandrogenism, and central obesity.